rifadin rifampicin 300mg capsules blister pack
sanofi-aventis australia pty ltd - rifampicin, quantity: 300 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.
rifadin rifampicin 150mg capsules blister pack
sanofi-aventis australia pty ltd - rifampicin, quantity: 150 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.
rifampicin 300mg capsules
a a h pharmaceuticals ltd - rifampicin - oral capsule - 300mg
rifampicin 300mg capsules
viatris uk healthcare ltd - rifampicin - oral capsule - 300mg
rifampicin 300mg capsules
kent pharma (uk) ltd - rifampicin - oral capsule - 300mg
rifampicin 300mg capsules
alliance healthcare (distribution) ltd - rifampicin - oral capsule - 300mg
rifampicin 150mg capsules
a a h pharmaceuticals ltd - rifampicin - oral capsule - 150mg
rifampicin 150mg capsules
viatris uk healthcare ltd - rifampicin - oral capsule - 150mg
rifampicin 150mg capsules
kent pharma (uk) ltd - rifampicin - oral capsule - 150mg
rifampicin 150mg capsules
alliance healthcare (distribution) ltd - rifampicin - oral capsule - 150mg